⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15809104 | 0.84 | — | — | |
| SCHEMBL1809381 | 0.80 | — | — | |
| SCHEMBL11997180 | 0.77 | — | — | |
| SCHEMBL186340 | 0.74 | — | — | |
| SCHEMBL16992630 | 0.74 | — | — | |
| SCHEMBL13399574 | 0.65 | — | — | |
| SCHEMBL3628169 | 0.65 | — | — | |
| SCHEMBL27883711 | 0.65 | — | — | |
| SCHEMBL27465028 | 0.64 | — | — | |
| SCHEMBL7165116 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | NOVARTIS AG (CH) | 2019-11-19 | — | — | US | disclosed |
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-9676749-B2 | Compositions and methods for cancer detection and treatment | OHIO STATE INNOVATION FOUNDATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676749-B2 | Compositions and methods for cancer detection and treatment | OHIO STATE INNOVATION FOUNDATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160052910-A1 | COMPOSITIONS AND METHODS FOR CANCER DETECTION AND TREATMENT | OHIO STATE INNOVATION FOUNDATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052910-A1 | COMPOSITIONS AND METHODS FOR CANCER DETECTION AND TREATMENT | OHIO STATE INNOVATION FOUNDATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-9096499-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-04 | — | — | US | disclosed |
| US-9044432-B2 | Compositions and methods for cancer detection and treatment | OHIO STATE INNOVATION FOUNDATION (US) | 2015-06-02 | — | — | US | disclosed |
| US-8143412-B2 | Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-03-27 | — | — | US | disclosed |
| US-8119827-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110053992-A1 | Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-03-03 | — | — | US | disclosed |
| US-20110053992-A1 | Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-03-03 | — | — | US | disclosed |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-27 | — | — | US | disclosed |
| US-7745468-B2 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | Board of Regents, University of Texas Systems The (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | MOLECULIN, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | MOLECULIN, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010005807-A2 | NOVEL INHIBITORS OF PROLIFERATION AND ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STATS) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20070232668-A1 | Orally Bioavailable Caffeic Acid Related Anticancer Drugs | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-04 | — | — | US | disclosed |